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controls for comorbid conditions—no controls, controls
for all conditions, and controls for conditions thought to
be unrelated to arthritis.
RESULTS: In the study 5920 OA and 1310 RA patients
were identified. OA patients cost between 1.50 and 2.56
times more than non-arthritis patients, while RA patients
cost between 2.21 and 3.07 times more than non-arthritis
patients. Based on assumptions about the relationships be-
tween comorbid conditions and arthritis, our point esti-
mate is that OA adds $80 per-patient-per-month (PPPM)
compared to non-arthritis patients, while RA adds $109
PPPM compared to non-arthritis patients.
CONCLUSIONS: Arthritis increases the costs of care sig-
nificantly. Existing estimation approaches either underes-
timate the cost of arthritis by including the cost of all co-
morbid conditions, or overestimate the cost by excluding
the cost of all comorbid conditions. Our approach, which
controls for only those comorbid conditions which are
unrelated to arthritis, yields a cost estimate that falls be-
tween those estimated by existing approaches and is be-
lieved to be more precise.
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OBJECTIVES: The primary aims of SCAP in Australia
are to: contribute to the establishment of a schizophrenia
outcomes database; evaluate which model of healthcare
results in better clinical outcomes and quality of life in a
naturalistic setting; and evaluate the cost of healthcare
for patients with schizophrenia. Emphasis is given to
measuring the utilization of mental healthcare services.
METHODS: SCAP is a prospective, naturalistic, non-ran-
domized 3-year follow-up study of 350 patients, with a
diagnosis of schizophrenia, schizoaffective disorder, or
schizophreniform disorder. Data on utilization of health-
care resources and costs involved in the treatment of
schizophrenia will be obtained from patient records and
from a number of state and federal databases. These cover
all healthcare services used: in hospital and out of hospi-
tal; medications and community services. The initial find-
ings based on 6-month data for the first 50 subjects were
used for a pilot study.
RESULTS: The average direct medical care cost of treating
patients over the period was calculated at A$5500. Hospi-
talizations accounted for 85% of the costs. Medications
used while the patient was in the community care ac-
counted for only 2.5% of the total costs. Ten percent of
the patients utilized over 30% of the treatment resources.
CONCLUSIONS: A full clinical costing could be under-
taken by linking data from a range of payments and activ-
ity data sets in Australia. SCAP will provide unique data
on the social and economic cost of schizophrenia. SCAP is
unique because it provides the opportunity to simulta-
neously explore a broad range of schizophrenia research
questions in a variety of settings across time. Further the
SCAP results will be drawn from a naturalistic setting and
this will enhance the generalizability of the results.
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Morris LS, Lichtenstein M, Smith J
IMS HEALTH, Plymouth Meeting, PA, USA
OBJECTIVES: Alzheimer’s disease is a growing concern
due to aging of the US population and the medical re-
sources that are consumed by these patients. This study
evaluated the changes in resource utilization for newly di-
agnosed Alzheimer’s patients and a control group.
METHODS: Using an employer claims database, pa-
tients newly diagnosed with Alzheimer’s (ICD-9-CM
331.0) in 1996 (N  265) and not previously treated
with donepezil or tacrine were followed for 12 months
preceding and following diagnosis to determine medical
resource utilization. An age and gender matched control
group was constructed. Patients were 70 years of age or
older and were required to be continuously enrolled for a
24-month period.
RESULTS: Average charges per patient for the test group
were $8292 prior to diagnosis and $14,620 following
diagnosis. The control group had average charges per pa-
tient of $6199 in the pre-period and $7232 in the post
period. Charges for drugs of interest, ER visits, inpatient
hospitalizations, labs, nursing homes, outpatient services,
and other medical resources were broken down. In the
test group following diagnosis, there was a 170% in-
crease in the charge per patient for nursing home charges.
Nursing home charges for the test group following diag-
nosis accounted for 23.5% of the overall average
charges. In the control group, nursing home charges ac-
counted for only 5% of the overall average charges.
There were also increases in charges for ER visits, inpa-
tient hospitalizations, and outpatient services for the test
group following diagnosis.
CONCLUSIONS: Patients newly diagnosed with Alzhe-
imer’s consume more medical resources, mostly through
inpatient, ER, and nursing home services. Identification
of improved therapies aimed at keeping patients out of
nursing homes could produce significant cost savings.
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OBJECTIVES: The purpose was to estimate the EI of VM
in the United States from payer and societal perspectives.
METHODS: The EI of VM was estimated by applying
the cost and probability estimates of events in a decision
analytic framework (DAF). DAF development and prob-
ability of events were obtained from an expert panel. Di-
rect medical costs were estimated by charge data ob-
tained from the 1996 Pennsylvania Medicaid database
and the Drug Topics Red Book. Indirect costs were ob-
tained in terms of activity restricted days (ARDs) as esti-
mated by the panel. ARDs were defined as the average
number of days patients with VM missed school/work or
normal activities. Monte Carlo simulations were used to
generate the distribution of charges for estimating the EI
of VM on a per patient basis. The per patient EI was then
extrapolated to the US population. Sensitivity analyses
(one-way) were conducted by varying the probability val-
ues at the dominant nodes, nodes with high-cost, and
nodes with the largest ranges.
RESULTS: An episode of VM poses direct medical costs
to payers ranging from $4500 to $5700 in adult patients
and $5000 to $5300 in pediatric patients. Similarly, an
episode of VM poses an average of 5.6 to 7.5 ARDs.
These results were stable across the sensitivity parameters
tested.
CONCLUSIONS: Management of VM imposes a sizable
economic burden from both the payer and societal per-
spectives. Based on a conservatively estimated 250,000
annual cases of VM in the United States, the economic
burden to payers in terms of direct costs exceeds $1 bil-
lion per year. The additional economic burden in terms
of indirect costs to society would approximate 1.5 mil-
lion ARDs.
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Prior estimates of the cost of epilepsy have been based on
expert panels and decision-analysis models, but not on
national data.
OBJECTIVES: To estimate annual medical resource use
and payer costs of inpatient and outpatient medical care
related to epilepsy.
METHODS: Using three sources of national survey data
from 1992 to 1996—1) the Healthcare Cost and Utiliza-
tion Project Nationwide Inpatient Sample (NIS), 2) the
National Ambulatory Medical Care Survey (NAMCS),
and 3) the National Hospital Ambulatory Medical Care
Survey (NHAMCS)—we identified all inpatient admis-
sions and outpatient encounters with a primary ICD-9-
CM diagnosis code, and alternatively, any diagnosis code,
of epilepsy (345.1–345.9) or convulsions (780.3). We
then assigned an allowed charge to each encounter by
matching it to an encounter in Medicare’s Standard Ana-
lytic File (SAF). Annual rates of medical resource use and
payer costs were then estimated, by diagnosis and payer
type.
RESULTS: The annual payer cost of inpatient and outpa-
tient care with a primary diagnosis of epilepsy or convul-
sions was approximately $4.8 billion. Medicare accounted
for 35% of these costs followed by private insurers/HMOs
(28%) and Medicaid (27%). Encounters with a primary
diagnosis of convulsions accounted for 73% of costs,
while those coded as epilepsy accounted for the remaining
27%. Annual cost of care with any diagnosis code for epi-
lepsy or convulsions was $22 billion.
CONCLUSION: Even without accounting for medica-
tions, the costs of epilepsy appear higher than previously
estimated. This analysis provides a national estimate of
the inpatient and outpatient costs of epilepsy.
SCREENING PROGRAMS
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MANAGED CARE MODEL
Sampson JM, Schmitt JB
Department of Veterans Affairs, Alexandria, LA, USA
Colon cancer is a common cause of malignancy in men
and women. The incidence has been increasing over the
past several decades. Fecal occult blood testing has been
shown in several randomized controlled studies to reduce
the rate of colorectal cancer. The US Preventive Task
Force has recommended universal screening after the age
of 50. More than 150,000 new cases of colon cancer are
diagnosed each year. The mortality rate continues to be
greater than 50% in these diagnosed cases. Various fecal
occult blood tests (FOBT) used in screening colorectal
cancer have reduced mortality by 15–30%.
OBJECTIVE: The purpose of this study was to assess the
effectiveness of fecal occult blood testing in reducing the
mortality rate from colorectal cancer as part of a man-
aged care program. The suggested number of patients
needed for screening to prevent one death from colon can-
cer is 1374 for 5 years. The cost of FOBT is relatively in-
